Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Perrone

Showing results (91-100 of 272) with videos related to

Pageof 28
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|May 14, 2011
Pharmacokinetic evaluation of zoledronic acidAntonella De Luca, Luana Lamura, Marianna Gallo, et al.
Expert Opinion on Biological Therapy|January 7, 2014
New biological treatments for gynecological tumors: focus on angiogenesisGennaro Daniele, Massimo Di Maio, Maria Carmela Piccirillo, et al.
Anticancer Research|November 3, 2004
Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro?Antonella De Luca, Michele Grassii, Monica R Maiello, et al.
Oncology|May 22, 2003
Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? a single-center phase 2 studyEmanuela Rossi, Francesco Perrone, Vincenzo Labonia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancerFrancesco Perrone, Ermelinda De Maio, Paolo Maione, et al.
Current Pharmaceutical Design|November 7, 2013
Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better…Massimo Di Maio, Alessandro Morabito, Maria Carmela Piccirillo, et al.
Frontiers in Bioscience : a Journal and Virtual Library|December 22, 2005
The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancerMassimo Di Maio, Carmela Pisano, Rosa Tambaro, et al.
Expert Opinion on Investigational Drugs|November 5, 2010
New drugs in advanced non-small-cell lung cancer: searching for the correct clinical developmentMassimo Di Maio, Alessandro Morabito, Maria Carmela Piccirillo, et al.
Clinical Lung Cancer|April 12, 2015
Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Lodovico Balducci, Fortunato Ciardiello, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 22, 2022
Out-of-pocket costs sustained in the last 12 months by cancer patients: an Italian survey-based study on individual expenses between 2017 and 2018Roberto Lillini, Francesco De Lorenzo, Paolo Baili, et al.
Pageof 28

Showing results (91-100 of 272) with videos related to

Sort By:
Pageof 28
Expert Opinion on Drug Metabolism & Toxicology|May 14, 2011
Pharmacokinetic evaluation of zoledronic acidAntonella De Luca, Luana Lamura, Marianna Gallo, et al.
Expert Opinion on Biological Therapy|January 7, 2014
New biological treatments for gynecological tumors: focus on angiogenesisGennaro Daniele, Massimo Di Maio, Maria Carmela Piccirillo, et al.
Anticancer Research|November 3, 2004
Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro?Antonella De Luca, Michele Grassii, Monica R Maiello, et al.
Oncology|May 22, 2003
Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? a single-center phase 2 studyEmanuela Rossi, Francesco Perrone, Vincenzo Labonia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancerFrancesco Perrone, Ermelinda De Maio, Paolo Maione, et al.
Current Pharmaceutical Design|November 7, 2013
Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better…Massimo Di Maio, Alessandro Morabito, Maria Carmela Piccirillo, et al.
Frontiers in Bioscience : a Journal and Virtual Library|December 22, 2005
The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancerMassimo Di Maio, Carmela Pisano, Rosa Tambaro, et al.
Expert Opinion on Investigational Drugs|November 5, 2010
New drugs in advanced non-small-cell lung cancer: searching for the correct clinical developmentMassimo Di Maio, Alessandro Morabito, Maria Carmela Piccirillo, et al.
Clinical Lung Cancer|April 12, 2015
Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Lodovico Balducci, Fortunato Ciardiello, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 22, 2022
Out-of-pocket costs sustained in the last 12 months by cancer patients: an Italian survey-based study on individual expenses between 2017 and 2018Roberto Lillini, Francesco De Lorenzo, Paolo Baili, et al.
Pageof 28